Abstract
Numerous drugs have the potential to adversely influence a patient’s sense of taste, either by decreasing function or producing perceptual distortions or phantom tastes. In some cases, such adverse effects are long lasting and cannot be quickly reversed by drug cessation. In a number of cases, taste-related adverse effects significantly alter the patient’s quality of life, dietary choices, emotional state and compliance with medication regimens. In this review, we describe common drug-related taste disturbances and review the major classes of medications associated with them, including antihypertensives, antimicrobials and anti-depressants. We point out that there is a dearth of scientific information related to this problem, limiting our understanding of the true nature, incidence and prevalence of drug-related chemosensory disturbances. The limited data available suggest that large differences exist among individuals in terms of their susceptibility to taste-related adverse effects, and that sex, age, body mass and genetic variations in taste sensitivity are likely involved. Aside from altering drug usage, management strategies for patients with taste-related adverse effects are sorely needed. Unfortunately, stopping a medication is not always an easy option, particularly when one is dealing with life-threatening conditions such as seizures, cancer, infection, diabetes mellitus and uncontrolled hypertension. Hopefully, the information contained in this review will sensitize physicians, researchers and drug manufacturers to this problem and will result in much more research on this pressing topic.
Similar content being viewed by others
References
Guggenheimer J. Oral manifestations of drug therapy. Dent Clin North Am 2002; 46(4): 857–68
Marks HM. Revisiting the origins of compulsory drug prescriptions. Am J Public Health 1995; 85(1): 109–15
Ciancio SG. Medications’ impact on oral health. J Am Dent Assoc 2004; 135(10): 1440–8
Physicians’ Desk Reference. Montvale (NJ): Medical Economics Company, Inc., 2005
Lewis IK, Hanlon JT, Hobbins MJ, et al. Use of medications with potential oral adverse drug reactions in community-dwelling elderly. Spec Care Dentist 1993; 13(4): 171–6
Shinkai RS, Hatch JP, Schmidt CB, et al. Exposure to the oral side effects of medication in a community-based sample. Spec Care Dentist 2006; 26(3): 116–20
Ahne G, Erras A, Hummel T, et al. Assessment of gustatory function by means of tasting tablets. Laryngoscope 2000 Aug; 110(8): 1396–401
Doty RL. Office procedures for quantitative assessment of olfactory function. Amer J Rhinol 2007; 21(4): 460–73
Deems DA, Doty RL, Settle RG, et al. Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center. Arch Otolaryngol Head Neck Surg 1991; 117(5): 519–28
Burdach KJ, Doty RL. The effects of mouth movements, swallowing, and spitting on retronasal odor perception. Physiol Behav 1987; 41(4): 353–6
Byrne BE. Oral manifestations of systemic agents. In: Ciancio SG, editor. ADA®/PDR® guide to dental therapeutics. 4th ed. Montvale (NJ): Thomson PDR, 2006: 835–9
Keiser HR, Henkin RI, Bartter FC, et al. Loss of taste during therapy with penicillamine. JAMA 1968; 203(6): 381–3
Fogan L. Griseofulvin and dysgeusia: implications? Ann Intern Med 2007; 74: 795–6
Bromley SM, Doty RL. Clinical disorders affecting taste: evaluation and management. In: Doty RL, editor. Handbook of olfaction and gustation. New York: Marcel Dekker, 2003: 935–57
Ishizaka T, Miyanaga Y, Mukai J, et al. Bitterness evaluation of medicines for pediatric use by a taste sensor. Chem Pharm Bull 2004; 52(8): 943–8
Schiffman SS, Zervakis J, Westall HL, et al. Effect of antimicrobial and anti-inflammatory medications on the sense of taste. Physiol Behav 2000; 69(4–5): 413–24
Juhlin L. Loss of taste and terbinafine [letter]. Lancet 1992; 339(8807): 1483
Beutler M, Hartmann K, Kuhn M, et al. Taste disorders and terbinafine [letter]. BMJ 1993: 307: 26
Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol 1998; 139(4): 747–8
Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laryngoscope 2005; 115(11): 2035–7
Stricker BH, Van RM, Sturkenboom MC, et al. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol 1996; 42(3): 313–8
Granger EM, Glendinning JI, Smith JC, et al. Behavioral and electrophysiological responses to NaCl in young and old fisch-er-344 rats. Chem Senses 1993; 18(4): 419–26
Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43(2): 259–84
Doty RL, Philip S, Reddy K, et al. Influences of antihypertensive and antihyperlipidemic drugs on the senses of taste and smell: a review. J Hypertens 2003; 21(10): 1805–13
Hellekant G, Danilova V, Ninomiya Y. Primate sense of taste: behavioral and single chorda tympani and glossopharyngeal nerve fiber recordings in the rhesus monkey, Macaca mulatta. J Neurophysiol 1997; 77(2): 978–93
Eiznhamer DA, Creagh T, Ruckle JL, et al. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin Trials 2002; 3(6): 435–50
Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav 2003; 7(2): 109–17
Eksborg S, Pal N, Kalin M, et al. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002; 38(4): 240–6
Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992; 36(4): 727–32
Hsyu PH, Pithavala YK, Gersten M, et al. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 2002; 2002 Feb; 46(2): 392–7
Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytome-galovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47(4): 1334–42
Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial. JAMA 1998; 279(24): 1962–7
Marshall S. Zinc gluconate and the common cold. Review of randomized controlled trials. Can Fam Phy 1998; 44: 1037–42
Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996; 125(2): 81–8
Tanaka M. Secretory function of the salivary gland in patients with taste disorders or xerostomia: correlation with zinc deficiency. Acta Otolaryngol Suppl 2002; (546): 134–41
Bergman U, Ostergren A, Gustafson AL, et al. Differential effects of olfactory toxicants on olfactory regeneration. Arch Toxicol 2002; 76(2): 104–12
Oakley B, Riddle DR. Receptor cell regeneration and connectivity in olfaction and taste. Exp Neurol 1992; 115(1): 50–4
Zain RB, Hanks CT. Morphological changes in taste buds of the fungiform papillae after a single dose of x-ray irradiation in rats. Malays J Pathol 1989; 11: 57–64
Nakamura H, Nonomura N, Fujiwara M, et al. Olfactory disturbances caused by the anti-cancer drug tegafur. Eur Arch Otorhinolaryngol 1995; 252(1): 48–52
Epstein JB, Phillips N, Parry J, et al. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2002; 30(11): 785–92
Wickham RS, Rehwaldt M, Kefer C, et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999; 26(4): 697–706
Bergström U, Giovanetti A, Piras E, et al. Methimazole-induced damage in the olfactory mucosa: effects on ultrastructure and glutathione levels. Tox Path 2003; 31: 379–87
Kiewe P, Jovanovic S, Thiel E, et al. Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin. Ann Pharmacother 2004; 38(7–8): 1212–4
Hallman BL, Hurst JW. Loss of taste as a toxic effect of methimazole (tapazole) therapy: report of three cases [letter]. J Amer Med Assoc 1953; 152: 322
McConnell RJ, Menendez CE, Smith FR, et al. Defects of taste and smell in patients with hypothyroidism. Am J Med 1975; 59(3): 354–64
Genter MB, Owens DM, Carlone HB, et al. Characterization of olfactory deficits in the rat following administration of 2,6-dichlorobenzonitrile (dichlobenil), 3,3′-iminodipropionitrile, or methimazole. Fundam Appl Toxicol 1996; 29(1): 71–7
Xu W, Slotnick B. Olfaction and peripheral olfactory connections in methimazole-treated rats. Behav Brain Res 1999; 102(1–2): 41–50
Sitzia J, North C, Stanley J, et al. Side effects of CHOP in the treatment of non-Hodgkins’s lymphoma. Cancer Nurs 1997; 20(6): 430–9
Brosvic GM, Doty RL, Rowe MM, et al. Influences of hypothyroidism on the taste detection performance of rats: a signal detection analysis. Behav Neurosci 1992; 106(6): 992–8
Boyd I. Captopril-induced taste disturbance [letter]. Lancet 1993; 342: 304
Zervakis J, Graham BG, Schiffman SS. Taste effects of lingual application of cardiovascular medications. Physiol Behav 2000 Jan; 68(3): 405–13
Griffin JP. Drug-induced disorders of taste. Adverse Drug React Toxicol Rev 1992; 11(4): 229–39
DiBianco R. ACE inhibitors in the treatment of heart failure. Clin Cardiol 1990; 13 (6 Suppl. 7): VII32–8
Grosskopf I, Rabinovitz M, Garty M, et al. Persistent captopril-associated taste alteration [letter]. Clin Pharm 1984; 3(3): 235
McNeil JJ, Anderson A, Christophidis N, et al. Taste loss associated with oral captopril treatment. BMJ 1979; 2: 1555–6
Unnikrishnan D, Murakonda P, Dharmarajan TS. If it is not cough, it must be dysgeusia: differing adverse effects of angio-tensin-converting enzyme inhibitors in the same individual. J Am Med Dir Assoc 2004; 5(2): 107–10
Heeringa M, van PE. Reversible dysgeusia attributed to losartan [letter]. Ann Intern Med 1998; 129(1): 72
Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan [letter]. Lancet 1996; 347(8999): 471–2
Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydroclorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75(12): 793–5
Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51(5): 820–45
Levenson JL, Kennedy K. Dysosmia, dysgeusia, and nifedipine. Ann Intern Med 1985; 102(1): 135–6
Guggenheimer J. Oral manifestations of drug therapy. Dent Clin North Am 2002; 46: 857–68
Appel LJ. The verdict from ALLHAT: thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288(23): 3039–42
Roitman MF, Bernstein IL. Amiloride-sensitive sodium signals and salt appetite: multiple gustatory pathways. Am J Physiol Regul Integr Comp Physiol 1999; 276(6): 1732–8
Roper SD. Signal transduction and information processing in mammalian taste buds. Pflugers Arch 2007; 454(5): 759–76
Anand KK, Zuniga JR. Effect of amiloride on suprathreshold NaCl, LiCl, and KCl salt taste in humans. Physiol Behav 1997; 62(4): 925–9
Mattes RD, Christensen CM, Engelman K. Effects of therapeutic doses of amiloride and hydrochlorothiazide on taste, saliva, and salt intake in normotensive adults. Chem Senses 1988; 13: 33–44
McMurdo ME, Hutchinson GL, Lindsay G. Taste disturbance with acetazolamide. Lancet 1990; 336(8724): 1190–1
Leaf A, Schwartz WB, Relman AS. Oral administration of a potent carbonic anhydrase inhibitor (Diamox): I. Changes in electrolyte and acid-base balance. N Engl J Med 1954; 250(18): 759–64
Kennedy WA, Laurier C, Gautrin D, et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epid 2000; 53(97): 696–701
Mitchell JC, Counselman FL. A taste comparison of three different liquid steroid preparations: prednisone, prednisolone, and dexamethasone. Acad Emerg Med 2003; 10(4): 400–3
Bachert C, El Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89(3): 292–7
Regan TD, Lewis D, Norton SA. Taste comparison of corticosteroid suspensions. J Drugs Dermatol 2006; 5(9): 835–7
Kratskin IL, Kimura Y, Hastings L, et al. Chronic dexamethasone treatment potentiates insult to olfactory receptor cells produced by 3-methylindole. Brain Res 1999; 847(2): 240–6
Schiffman SS, Graham BG, Suggs MS, et al. Effect of psychotropic drugs on taste responses in young and elderly persons. Ann NY Acad Sci 1998; 855: 732–7
Schiffman SS, Zervakis J, Suggs MS, et al. Effect of medications on taste: example of amitriptyline HC1. Physiol Behav 1999; 66(2): 183–91
Ackerman BH, Kasbekar N. Disturbances of taste and smell induced by drugs. Pharmacotherapy 1997; 17: 482–96
Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995; 40(11): 983–9
Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3(2): 131–40
Padala KP, Hinners CK, Padala PR. Mirtazapine therapy for dysgeusia in an elderly patient. J Clin Psychiatry 2007; 8: 178–80
Scharf MB, Roth PB, Dominguez RA, et al. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in patients with insomnia. J Clin Pharmacol 1990; 30(5): 461–7
Berridge KC, Peciña S. Benzodiazepines, appetite, and taste palatability. Neurosci Biobehav Rev 1995; 19(1): 121–31
Caldwell EE, Wallace P, Taylor SP. Use of an analog task to study effects of diazepam on taste perception, consummatory behaviors, and risk taking in a social context. J Gen Psychol 2004; 13(2): 101–17
Abdullahi M, Radfar M. A review of drug induced oral reactions. J Cont Dent Prac 2005; 4(1): 1–22
Tyssen A, Remmerie B, Eng C, et al. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther 2007; 29(2): 290–304
Bressler B. An unusual side-effect of lithium. Psychosomatics 1980; 21(8): 688–9
Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort: 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiat Scand 1988; 78(4): 434–41
Duffield JE. Side effects of lithium carbonate [letter]. BMJ 1973; 1(5851): 491
Himmelhoch JM, Hanin I. Letter: Side effects of lithium carbonate. BMJ 1974; 4(5938): 233
Grupta KD, Jefferson JW. Lithium and “accidentally” induced food aversion [letter]. J Clin Psychiatry 1980; 41(10): 364
Mizielinska SM. Ion channels in epilepsy. Biochem Soc Trans 2007; 35 (Pt 5): 1077–9
Onat F, Ozkara C. Adverse effects of new antiepileptic drugs. Drugs Today 2004; 40(4): 325–42
Zeller JA, Machetanz J, Kessler C. Ageusia as an adverse effect of phenytoin treatment. Lancet 1998; 352: 68
Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291(8): 965–73
Silberstein S, Loder E, Forder G, et al. The impact of migraine on daily activities: effect of topiramate compared to placebo. Curr Med Res Opin 2006; 22: 1021–9
Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41(10): 968–75
Nakazato Y, Imai K, Abe T, et al. Unpleasant sweet taste: a symptom of SIADH caused by lung cancer. J Neurol Neurosurg Psychiat 2006; 77(3): 405–6
Panayiotou H, Small SC, Hunter JH, et al. Sweet taste (dysgeusia). The first symptom of hyponatremia in small cell carcinoma of the lung. Arch Intern Med 1995; 155(12): 1325–8
Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J 1999; 44: 219–32
Mata F. Effect of dextro-amphetamine on bitter taste threshold. J Neuropsychol 1963; 4: 315–20
Saini T, Edwards PC, Kimmes NS, et al. Etiology of xerostomia and dental caries among methamphetamine abusers. Oral Health Prev Dent 2005; 3(3): 189–95
Doty RL, Ferguson-Segall M. Odor detection performance of rats following d-amphetamine treatment: a signal detection analysis. Psychopharmacology 1987; 93(1): 87–93
Doty RL, Li C, Bagla R, et al. SKF 38393 enhances odor detection performance. Psychopharmacology 1998; 136(1): 75–82
Doty RL, Risser JM. Influence of the D-2 dopamine receptor agonist quinpirole on the odor detection performance of rats before and after spiperone administration. Psychopharmacology 1989; 98(3): 310–5
Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26(7): 793–9
Enghusen PH, Loft S, Andersen JR, et al. Disulfiram therapy — adverse drug reactions and interactions. Acta Psychiatr Scand Suppl. 1992; 369: 59–65
Fantino M, Hosotte J, Apfelbaum M. An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am J Physiol 1986; 251(1): R91–6
Bertino M, Beauchamp GK, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. Am J Physiol 1991 Jul; 261 (1 Pt 2): R59–63
Komorowski JM, Komorowska A. Naloxone modulates gustatory perception, but not insulin and c-peptide release, in shamfed human-subjects. Int J Obes 1986; 10(2): 83–9
Gaskell BA. Nonneoplastic changes in the olfactory epithelium: experimental studies. Environ Health Perspect 1990; 85: 275–89
Reed CJ. Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev 1993; 25(1–2): 173–205
Frye RE, Schwartz BS, Doty RL. Dose-related effects of cigarette smoking on olfactory function. JAMA 1990; 263(9): 1233–6
Matulionis DH. Ultrastructure of olfactory epithelia in mice after smoke exposure. Ann Otolaryngol 1974; 83: 192–201
Patel SJ, Bollhoefer AD, Doty RL. Influences of ethanol ingestion on olfactory function in humans. Psychopharmacology 2004; 171(4): 429–34
Mair RG, McEntee WJ, Doty RL. Olfactory perception in Korsakoff s psychosis: correlation with brain noradrenergic activity. Neurology 1983; 33 Suppl. 2: 64–5
Vent J, Robinson AM, Gentry-Nielsen MJ, et al. Pathology of the olfactory epithelium: smoking and ethanol exposure. Laryngoscope 2004; 114(8): 1383–8
Murray C, Solish N. Metallic taste: an unusual reaction to botulinum toxin A. Dermatol Surg 2003; 29: 562–3
Mandel ID. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989; 119(2): 298–304
Sarinopoulos I, Dixon GE, Short SJ, et al. Brain mechanisms of expectation associated with insula and amygdala response to aversive taste: implications for placebo. Brain Behav Immun 2006; 20(2): 120–32
Glendinning JI. Is the bitter rejection response always adaptive? Physiol Behav 1994; 56(6): 1217–27
Drewnowski A. The science and complexity of bitter taste. Nutr Rev 2001; 59(6): 163–9
Mattes RD. Influences on acceptance of bitter foods and beverages. Physiol Behav 1994; 56(6): 1229–36
Liem DG, De GC. Sweet and sour preferences in young children and adults: role of repeated exposure. Physiol Behav 2004; 83(3): 421–9
Liem DG, Bogers RP, Dagnelie PC, et al. Fruit consumption of boys (8–11 years) is related to preferences for sour taste. Appetite 2006; 46(1): 93–6
Acknowledgements
This work was supported, in part, by Grants RO1 DC 004278 and RO1 AG 27496 from the National Institutes of Health, Bethesda, MD, USA. Dr Doty is a major shareholder in Sensonics, Inc., a manufacturer and distributor of tests of smell and taste function, and has served as a consultant to GlaxoSmithKline and Sepracor. Dr Bromley has participated on advisory panels and speaker bureaus for GlaxoSmithKline, Eli Lilly and Company, Pfizer, Cephalon and Forest Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doty, R.L., Shah, M. & Bromley, S.M. Drug-Induced Taste Disorders. Drug-Safety 31, 199–215 (2008). https://doi.org/10.2165/00002018-200831030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200831030-00002